Boston Scientific Slashes 2026 Earnings Forecast

Boston Scientific reported a significant increase in its first-quarter net income, which nearly doubled compared to the previous year, reaching $1.34 billion. This surge was propelled by continued global demand for its range of cardiology devices, including stents and catheters. Sales for the quarter climbed 12% to $5.2 billion, with cardiology device sales alone growing by 14% to $3.5 billion. The MedSurg unit also contributed positively, with sales up 7.8% to $1.7 billion.

Sales demonstrated broad-based strength, expanding in all geographic regions. Notably, the Latin America and Canada region experienced a substantial 19% sales increase. Despite this positive sales momentum, Boston Scientific revised its financial outlook downwards. The company has cut its projected 2026 adjusted earnings per share to a range of $3.34 to $3.41, a reduction from its earlier forecast of $3.43 to $3.49 per share.